How Often Should You Get a Low-Dose CT Scan?

For adults who qualify, the current U.S. guideline calls for a low-dose CT scan once a year. The U.S. Preventive Services Task Force recommends annual screening for people aged 50 to 80 who have a 20 pack-year smoking history and who currently smoke or quit within the past 15 years. That “once a year” recommendation, though, rests on specific trial evidence and comes with real caveats about who benefits, when to stop, and whether every eligible person truly needs the same interval.

Who Actually Qualifies for Screening

Low-dose CT for lung cancer screening is not a general-purpose scan that everyone should get periodically. It targets a specific high-risk group. The USPSTF’s 2021 update widened eligibility compared with the older 2013 criteria, which required a heavier smoking history of at least 30 pack-years and set the starting age at 55. The current version lowers both thresholds: you qualify starting at age 50 with a 20 pack-year history.¹ A pack-year is simply one pack per day for one year, so someone who smoked a pack a day for 20 years, or two packs a day for 10 years, meets the threshold.

If you have never smoked, or if your smoking history falls below that 20 pack-year cutoff, this screening is not recommended for you. The trial evidence showing a mortality benefit was drawn from heavy smokers, and the balance of benefit versus harm shifts unfavorably in lower-risk groups. The scan itself is quick and painless, but what follows a suspicious finding can involve months of follow-up imaging, biopsies, and anxiety. Without sufficient underlying risk of lung cancer, those downstream costs outweigh the chance of catching something early.

The Evidence Behind Annual Screening

The foundation for annual screening comes from the National Lung Screening Trial (NLST), a massive U.S. study that compared three rounds of annual low-dose CT to chest X-ray in over 53,000 high-risk adults. The low-dose CT group saw roughly 20% fewer lung cancer deaths than the X-ray group.² All-cause mortality was also about 7% lower in the CT group.³ That 20% reduction in lung cancer death is the number that anchors the entire screening recommendation.

The NLST screened participants once a year for three consecutive years. Because annual screening was the protocol that demonstrated the benefit, annual screening is what the guideline endorses. No major U.S. trial has tested, say, every-other-year LDCT head-to-head against annual LDCT, which means the annual recommendation is partly a product of the study design that happened to be tested rather than proof that every 12 months is the single best interval for every eligible person.

Does It Always Have to Be Every Year

The largest European trial, known as NELSON, took a different approach. Instead of screening at a fixed annual interval, it spaced out the scans: participants were screened at baseline, then at 1 year, then at 3 years, then at 5.5 years. Even with those widening gaps, the NELSON trial still found a meaningful reduction in lung cancer mortality, with roughly a 24% lower rate of lung cancer death in men screened versus those who were not.⁴ The number of people who needed to be screened to prevent one lung cancer death was about 130 over 10 years of follow-up.⁵

But the NELSON data also revealed a cost to stretching the interval too far. By the final screening round, which came after a 2.5-year gap, a higher proportion of cancers were detected at advanced stages compared with the earlier rounds that had shorter intervals. More cancers also appeared between scheduled screens, so-called interval cancers, during that longer gap.⁶ In other words, screening every 2.5 years let more aggressive cancers slip through and grow to dangerous sizes before the next scan could catch them. A 1- or 2-year interval performed much better at catching cancers early.

This is a meaningful nuance. Annual screening is the safest default for high-risk people, but there is a growing body of research suggesting that for some individuals, particularly those whose initial scans are clean and whose calculated risk is on the lower end of the eligible range, a biennial (every two years) interval might preserve most of the benefit while reducing the cumulative burden of repeated scans.

Personalizing the Interval

One area gaining traction in screening research is risk-adapted scheduling. Rather than screening everyone at the same fixed interval, the idea is to use a person’s individual risk profile, including their initial scan results, to decide how often they should come back. Researchers have extended existing risk-prediction models to incorporate screening results. If your baseline scan is clean and your calculated lung cancer risk is below a certain threshold, your next scan could be pushed to two or even three years out. If your risk is higher or a nodule is found, you stay on an annual or more intensive schedule.⁷

Economic modeling supports this approach. A 2025 study found that for people at moderate risk, adaptive strategies starting with biennial screening were the most cost-effective option up to a willingness-to-pay threshold of $100,000 per quality-adjusted life year gained. Annual screening became the preferred strategy only at higher spending thresholds.⁸ Another analysis found that when factoring in the anxiety and follow-up burden of indeterminate scan findings, biennial strategies dominated the cost-effectiveness frontier more consistently than annual ones.⁹

Risk-adapted screening has not yet replaced the flat annual recommendation in U.S. guidelines, but it represents the direction the field is heading. If your doctor discusses spacing out your scans after a clean result, that conversation is grounded in real evidence, not corner-cutting.

When to Stop Screening

The recommendation includes clear stopping rules. You should discontinue screening once you have not smoked for 15 years, or if you develop a health problem that substantially limits your life expectancy or your ability or willingness to undergo curative lung surgery.¹ The upper age boundary is 80.

These criteria exist because screening only helps if you can act on what it finds. If a person has severe heart failure, advanced dementia, or another condition that makes surgery or treatment impractical, detecting an early-stage lung cancer does not translate into a survival benefit. It just adds diagnostic procedures, worry, and cost with no realistic upside. The 15-year quit threshold reflects the declining lung cancer risk in former smokers as years accumulate after quitting. At some point, your risk drops enough that the harms of continued screening, including false positives and radiation, outweigh the shrinking benefit.

The Cumulative Problem of False Positives

One of the most striking aspects of LDCT screening is how common false alarms are. In the NLST, about a quarter of scans in the first two rounds flagged something that turned out not to be cancer.¹⁰ Across different studies, false-positive rates at baseline ranged from about 8% to nearly 50%, depending heavily on how programs defined a “positive” result and what nodule size cutoff they used.¹⁰

This matters for the “how often” question because false positives accumulate. After a single low-dose CT, your cumulative chance of at least one false positive was about 21%. After two scans, it climbed to 33%.¹¹ With annual screening over many years, a large fraction of people will eventually be told something suspicious was found, only to learn later it was nothing. The good news is that the rate tends to drop at later screening rounds as previously identified stable nodules get catalogued. The NLST saw false-positive rates fall from about 26% at baseline to 16% in the third round.¹²

Most false positives lead only to a repeat CT a few months later to check for changes, not to anything invasive. In the NLST, invasive procedures like biopsies or surgeries followed false-positive results in fewer than 3% of cases, and serious complications from those procedures occurred in a very small minority.¹² Still, the anxiety of being told there is a spot on your lung is real, even when it resolves without incident.

The Psychological Side of Repeated Scans

Getting screened regularly means living with a cycle of anticipation and relief, or in some cases, prolonged uncertainty. Research from multiple screening programs has found that the screening appointment itself can trigger lung cancer-specific distress. In one cohort, over 40% of participants reported elevated distress right before their scan. In the NELSON trial, participants experienced a significant increase in intrusive thoughts about lung cancer while waiting for results, with about half reporting dread or discomfort.¹³

For people who receive an indeterminate result, meaning something was found but it is not clearly cancer and needs follow-up, the psychological impact is more pronounced. These individuals showed higher anxiety and depression scores compared with those who got clean results, and that effect persisted for months.¹⁴ In a separate trial using a blood-based screening test followed by imaging, people who tested positive had more than twice the odds of frequently worrying about lung cancer even six months later, compared with those who tested negative.¹⁵

None of this means screening is not worth it. But it does mean that the “how often” question is not purely medical. Every additional round of screening renews this emotional cycle. For people with clean scans and declining risk, spacing out that cycle even slightly could meaningfully improve quality of life without sacrificing much protection.

Radiation Exposure From Repeated Scans

A low-dose CT delivers far less radiation than a standard diagnostic chest CT. But over 25 or more years of annual screening, the cumulative dose adds up. A simulation study estimated that annual screening from age 55 to 75 would detect about 112 lung cancers while causing roughly 2 radiation-induced cancers among every 100,000 women screened. Starting screening at 50 and running to 75 increased the radiation-induced cancers to about 3.4 per 100,000.¹⁶ A separate phantom study found that annual scans from 55 to 80 increased lifetime cancer risk by about 0.13% in men and 0.30% in women.¹⁷

Those are small numbers in the context of the benefit. The ratio of cancers detected to cancers caused by the screening itself is heavily favorable. But the risk is not zero, and it tilts the calculus slightly more toward longer intervals or earlier discontinuation for people whose risk profile is on the lower end. Newer ultra-low-dose CT protocols using artificial intelligence-based image reconstruction are now demonstrating that radiation doses can be cut by 90% or more while still detecting pulmonary nodules reliably.¹⁸ If these protocols become standard, the radiation argument for spacing out scans weakens substantially.

Real-World Adherence Is Dismally Low

Whatever the recommended interval, the bigger practical problem is that most eligible people do not come back for their next scan at all. In a large analysis of over a million people screened, adherence to follow-up screening was only about 22%.¹⁹ A separate study of a hospital-based program found that among patients with negative results, just under 24% returned within a year, and a mere 3% came back after two years.²⁰

The people most likely to stick with screening are those who have already been told something was found. In one program, adherence climbed from 33% for patients with completely clean scans to 78% or higher for those with suspicious nodules.²¹ Former smokers were also more likely to return than current smokers. The implication is sobering: the people most at risk, active smokers with clean initial scans, are the least likely to follow through. Screening can only save lives if people actually show up, which makes the practical answer to “how often” less about guidelines and more about systems that make returning easy and accessible.

Disparities in Who Gets Screened

The adherence problem is not evenly distributed. Black patients who were referred to lung cancer screening programs were significantly less likely to actually receive LDCT compared with White patients, even after adjusting for individual risk factors and neighborhood-level characteristics.²² A separate study comparing the proportion of Black individuals screened against the estimated proportion who were eligible found a significant shortfall.²³ Hispanic patients also showed lower adherence rates in registry data.¹⁹

Because lung cancer mortality is already highest among Black men in the U.S., screening gaps risk widening existing disparities rather than closing them. The reasons are complex: access to screening facilities, insurance barriers, trust in the health care system, and differences in how clinicians discuss screening with patients all play a role. Guidelines can recommend annual screening, but that recommendation is irrelevant to people who never get their first scan.

What About Nodules and Incidental Findings

Low-dose CT does not look only at cancer. It captures a cross-section of your chest, and radiologists regularly spot things unrelated to the primary question. In one review of screening records, about two-thirds of patients had at least one incidental finding. The most common were pulmonary findings not related to cancer, cardiovascular abnormalities like coronary artery calcification, and gastrointestinal findings. About 15% of scans led to further evaluation of an incidental finding, most commonly for cardiovascular issues.²⁴

For nodules found on lung cancer screening specifically, the Lung-RADS classification system guides follow-up. Nodules judged benign-appearing get routine annual follow-up. Suspicious ones may prompt a short-interval repeat scan in three months. However, there are questions about whether that short follow-up is always reassuring. A nodule that has not changed in three months could still be a slow-growing cancer, and a single stable reading can provide false reassurance.²⁵ This is another reason ongoing annual screening matters for eligible individuals: it creates a longitudinal record that makes subtle growth over time much easier to spot than any single follow-up scan can.

Blood Tests and the Future of Screening Intervals

One of the most promising developments is the use of blood-based biomarkers as a complement to CT. The idea is not to replace imaging but to help triage who needs it and when. Researchers have tested circulating tumor DNA fragments and microRNA panels as pre-screening tools. A blood test with high sensitivity could identify people whose cancer risk has changed between annual scans, allowing for a more targeted use of CT rather than blanket annual imaging for everyone.²⁶

In the BioMILD trial, a plasma microRNA classifier was used alongside LDCT. Among individuals who had suspicious findings on CT, the biomarker result could help distinguish those at genuinely elevated risk from those who could safely have their follow-up intervals extended.²⁷ These tools are still investigational and are not yet part of routine practice. But they represent a future in which “how often should you get a low-dose CT” might be answered not by a fixed calendar but by your individual biology at each visit.

Smoking Cessation and the Screening Visit

There is a synergy between lung cancer screening and quitting smoking that deserves attention. The screening visit itself is a contact point with the health care system, and researchers have advocated integrating smoking-cessation counseling directly into screening programs.²⁸ For current smokers, quitting remains the single most effective way to reduce lung cancer risk, far more powerful than screening alone. The two together, catching early cancers while simultaneously reducing the formation of new ones, create a compounding benefit.

This also ties back to the screening interval indirectly. If you quit and stay quit, the clock starts ticking toward the 15-year mark after which screening is no longer recommended. The annual visit is not just a scan; in well-designed programs, it is a recurring opportunity for a conversation about the one behavior change that matters most.